El-Hibri Fuad Blog

Archive for October 2011

ArabianBusiness.com focuses on the business of Arabs around the globe. The site’s Power 500 list identifies the world’s most influential Arabs, chronicling their achievements; a veritable who’s who among the most successful Arabs in the world. Men and women on the list contribute to a variety of fields including banking and finance, construction, media, culture and industry, science, and sports. Currently topping the list at #1 and #2 on the Power 500 are Saudi Arabian billionaire Prince Alwaleed and Google marketing chief, Wael Ghonim. It was Ghonim who recently became the face and driving force behind Egypt’s uprising, resulting in the dramaticousting of President Hosni Mubarak.

The Power 500 entries for those hailing from the Middle East have recently been on the rise with 69 on the list from the UAE, 62 from Saudi Arabia and 45 from Egypt. Lebanese businessman Fuad El Hibri with a focus on global health issues is #89 and Reem Acra, also Lebanese, is #448. El Hibri is the CEO and chairman of the US-based company Emergent BioSolution and is driving the search for critical vaccines for devastating diseases such as Meningitis B, typhoid, hepatitis B and tuberculosis. Acra is a fashion designer known especially for her bridal gowns, signature use of embroidery and celebrity customers. Her clothing is sold in exclusive stores such as Saks Fifth Avenue and Neiman Marcus.

ArabianBusiness.com also features a Fame List, currently topped by Nancy Ajram, the singer from Lebanon who has sold more than 30 million records and was named by Oprah Winfrey as one of the most influential personalities of the Middle East. Ajram is also a Goodwill Ambassador for UNICEF and Coca Cola’s first female spokesperson from the Middle East.


Fuad El-Hibri, chairman and chief executive officer of Emergent BioSolutions Inc.,(NYSE: EBS) announced that, in response to solicitation RFP-2011-N-13414, it has received an award to supply the U.S. government with 44.75 million doses of BioThrax(R) (Anthrax Vaccine Adsorbed) over a period of five years for a total value of up to $1.25 billion. BioThrax is the only vaccine licensed by the  U.S. Food and Drug Administration (FDA) to protect against anthrax infection.

Initial deliveries under this award are expected to begin in 2011 with 8.5 million doses scheduled to be delivered during the first year of a five-year contract. The company may modify the timing of deliveries depending on manufacturing yields and other factors.

“Emergent is proud to be able to contribute to the U.S. government’s program of protecting the nation from the threat of anthrax,” said  Fuad El-Hibri. “This 5-year award provides for uninterrupted supply of this critical biodefense countermeasure while addressing the government’s mandate to reduce spending across all programs. In coming to agreement, Emergent and the  Centers for Disease Control and Prevention worked diligently to establish business terms that incorporate substantial price concessions.”

About Emergent BioSolutions Inc.

Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent’s marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at  www.emergentbiosolutions.com.

About BioThrax

BioThrax is the only FDA-licensed vaccine for the prevention of anthrax infection. It is indicated for the active immunization of adults who are at high risk of exposure to anthrax. BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis. To date, Emergent has delivered over 55 million doses of BioThrax to the U.S. government and continues to deliver additional doses under active procurement contracts. Since 1998, over 10 million doses have been administered to more than 2.6 million military personnel. For full prescribing information, please visit  www.biothrax.com/prescribinginformation_biothrax_us.pdf.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue growth and net earnings for 2011, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax(R) procurement; our ability to obtain new BioThrax(R)sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax(R); our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance of our products; the success of preclinical studies and clinical trials of our product candidates and post-approval clinical utility of our products; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

SOURCE: Emergent BioSolutions Inc.

The El-Hibri Charitable Foundation has announced that internationally acclaimed author and educator  Gene Sharp has been selected as the 2011 recipient of the  El-Hibri Peace Education Prize. In 2009 Dr. Sharp was nominated for the  Nobel Peace Prize.

“Gene Sharp has dedicated his life to researching and teaching the strategic uses of nonviolent struggle against the forces of war, oppression and dictatorship,” noted Robert Buchanan, president of the El-Hibri Charitable Foundation. “His intellectual contributions to the field of nonviolent change cannot be overstated. The El-Hibri Charitable Foundation is pleased to recognize Dr. Gene Sharp for his thoughtful scholarship, his practical approach to nonviolence, and his extensive influence around the world.”

Sharp received a Doctor of Philosophy degree from Oxford and has held research appointments at Harvard University’s Center for International Affairs for more than thirty years. Among Sharp’s 14 books, his The Politics of Nonviolent Action in 1973 is recognized as the definitive study of nonviolent struggle. His best-known book is From Dictatorship to Democracy: A Conceptual Framework for Liberation published in 1993 and now appearing in 34 languages.

The 2011 El-Hibri Peace Education Prize will be awarded to Gene Sharp at a ceremony to be held on October 1st at the El-Hibri Charitable Foundation’s Washington, D.C. headquarters.The Prize, which includes an award of $15,000, is given annually by the foundation to honor an individual or organization that has made a significant contribution to the field of peace education. Sharp’s selection was made by a committee of peace education experts chaired by Dr. Awad Mubarak, President of  Nonviolence International.